D-0070-2023 Class III Terminated

Recalled by Acella Pharmaceuticals, LLC — Alpharetta, GA

FDA drug recall D-0070-2023 was initiated by Acella Pharmaceuticals, LLC on Nov 14, 2022 and is designated Class III. Reason for recall: Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode. The recall status is terminated (terminated Aug 21, 2024). Affected quantity: 637 cartons.

Recall details

Product Type
Drugs
Report Date
Nov 30, 2022
Initiation Date
Nov 14, 2022
Termination Date
Aug 21, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
637 cartons

Product description

Phenytoin Sodium Injection, USP, 250 mg/5 mL, NDC 42192-614-05, packaged in 10 x 5 mL vials per carton, NDC 42192-614-30, Rx only, Manufactured for: Acella Pharmaceuticals, LLC Alpharetta, GA 30005

Reason for recall

Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.

Distribution pattern

Nationwide in the USA.

Code information

Lot: E026A001 Exp. 06/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0070-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0070-2023. Report a data issue: hello@regdatalab.com.